A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques.

University of Maryland, Greenebaum Cancer Center, 655 West Baltimore Street, BRB 7-049, Baltimore, MD 21201, USA.
Stem Cells (Impact Factor: 7.13). 02/2001; 19(6):514-21. DOI: 10.1634/stemcells.19-6-514
Source: PubMed

ABSTRACT Leridistim, a member of the myelopoietin family of dual receptor agonists that binds interleukin-3 and G-CSF receptors, has been shown to enhance hematopoietic activity in rhesus monkeys above that observed with either cytokine alone or in combination. This study demonstrated the ability of a pegylated form of leridistim (peg-leridistim), administered s.c., as a single- or two-dose regimen separated by 4 or 7 days, to significantly improve neutrophil recovery following radiation-induced myelosuppression. Rhesus macaques were total body x-irradiated (250 kVp, TBI) to 600 cGy. Following TBI, two groups received peg-leridistim (n = 5) or leridistim (n = 4) at a dose of 600 microg/kg on day 1, while two other groups (both n = 4) received peg-leridistim at 200 microg/kg on day 1 and day 4, or day 1 and day 7. The irradiation controls (n = 7) received 0.1% autologous serum for 18 days. All peg-leridistim treatment schedules significantly improved all neutrophil-related parameters following TBI as compared with nontreated controls and were equivalent in effect when compared among themselves. Administration of a single high dose or two separate lower doses of peg-leridistim significantly improved neutrophil regeneration, in a manner equal to that of conventional daily or abbreviated every-other-day administration of leridistim in this nonhuman primate model of severe myelosuppression.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For individuals traveling in space, exposure to space radiation is unavoidable. Since adequate shielding against radiation exposure is not practical, other strategies for protecting the astronauts must be developed. Radiation is also an important therapeutic and diagnostic tool, and evidence from the clinical and experimental settings now shows a firm connection between radiation exposure and changes in cytokine and chemokine levels. These small proteins can be pro- or anti-inflammatory in nature and the balance between those two effects can be altered easily because of exogenous stresses such as radiation. The challenge to identify a common perpetrator, however, lies in the fact that the cytokines that are produced vary based on radiation dose, type of radiation, and the cell types that are exposed. Based on current knowledge, special treatments have successfully been designed by implementing administration of proteins, antibodies, and drugs that counteract some of the harmful effects of radiation. Although these treatments show promising results in animal studies, it has been difficult to transfer those practices to the human situation. Further understanding of the mechanisms by which cytokines are triggered through radiation exposure and how those proteins interact with one another may permit the generation of novel strategies for radiation protection from the damaging effects of radiation. Here, we review evidence for the connection between cytokines and the radiation response and speculate on strategies by which modulating cytokine responses may protect astronauts against the detrimental effects of ionizing radiations.
    Advances in Space Research 01/2007; 39:1019-1025. · 1.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mathematical modeling of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) pharmacokinetics (PK) and pharmacodynamics (PD) suggest that variations in the PEG-rHuMGDF treatment schedule could reduce the severity and duration of thrombocytopenia following myeloablation and bone marrow transplant (BMT). We tested this hypothesis in a rhesus monkey model of autologous (Au) bone marrow-derived mononuclear cell (BM-MNC) transplantation following lethal myeloablation. On day 0, animals were myeloablated by total body exposure to 920 cGy, 250 kVp x-irradiation (TBI). Four cohorts of animals were infused with 1 x 10(8) AuBM-MNC/kg body weight within 2 hours of TBI. The AuBMT-alone cohort received no cytokine, the daily dosage cohort received PEG-rHuMGDF (2.5 micro g/kg/day, s.c.) post TBI and AuBMT, and the pre/post-transplant cohort received PEG-rHuMGDF (2.5 micro g/kg/day, s.c.) pre (day -9 to day -5) and post TBI and AuBMT. The post-transplant PEG-rHuMGDF administration in the above cohorts was begun on day 1 post TBI and continued until platelet counts reached 200,000 micro l (range, 15-31 days). Another group received PEG-rHuMGDF (300 micro g/kg/day, s.c.) on days 1 and 3 only following TBI and AuBMT. The TBI controls received neither AuBMT nor cytokine therapy. In this model of AuBMT, with regard to the PEG-rHuMGDF administration schedule, the daily dosage of the post-transplant cohort did not significantly improve platelet recovery; the pre/post-transplant schedule and an abbreviated high-dosage, post-transplant schedule (days 1 and 3) significantly improved the duration and nadir of thrombocytopenia and platelet recovery. These data confirm predictions from PK/PD modeling of PEG-rHuMGDF that thrombocytopenia is preventable following AuBMT.
    Stem Cells 02/2003; 21(1):79-89. · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin E is composed of a family of eight isomers known as tocols; consisting of four tocopherols and four tocotrienols that exist in four isomeric forms: alpha (alpha), beta (beta), gamma (gamma), and delta (delta). Earlier we have demonstrated the radioprotective efficacy of the succinate ester of alpha-tocopherol (alpha-tocopherol succinate, TS). CD2F1 mice were injected subcutaneously with 400 mg/kg of TS and irradiated with different doses of 60Co gamma-radiation to determine its radioprotective efficacy. The dose reduction factor (DRF) for TS was also determined. We also investigated effects of TS on cytokine production by multiplex Luminex and message by quantitative RT-PCR. Peripheral blood cells were enumerated from irradiated (3 and 7 Gy) and non-irradiated mice. TS significantly protected mice against lethal doses of 60Co gamma-radiation and the DRF was 1.28. TS stimulated granulocyte-colony stimulating factor (G-CSF) with a peak at 24 h after drug injection, and also stimulated G-CSF message as judged by RT-PCR in bone marrow cells at 12 and 24 h after injection. Further, pancytopenia studies revealed that TS significantly reduced thrombocytopenia, neutropenia, and monocytopenia. TS had no significant effect on lymphocytes indicating that it may be helpful only for the myeloid cell compartments. The stimulation of G-CSF by TS supports its effects on myeloid cell compartments. Our studies indicate that TS may be developed as a radioprotectant for humans against the potentially lethal effects of radiation exposure.
    International immunopharmacology 10/2009; 9(12):1423-30. · 2.21 Impact Factor

Full-text (2 Sources)

Available from
Dec 11, 2014